LINAGLIPTIN 2.5mg. IP + METFORMIN 500mg. IP

An antidiabetic agent that is used to treat high blood sugar levels caused by type 2 diabetes. Increases the levels of incretin hormones in the body, which stimulate insulin release and decrease glucagon production (a hormone that raises blood sugar levels). (Maisha Kelly Freeman, 2011) Offers better glycemic control than monotherapy with either metformin or linagliptin alone. (Haak, 2015) Reduces the amount of glucose in your blood and increases insulin sensitivity. Linagliptin targets impaired β-cell function and excessive glucagon secretion and metformin improves hepatic insulin resistance. (S. A. Ross, 2014) Shows significant improvements in HbA1c and fasting plasma glucose compared with metformin alone. (Haak, 2015) Elicits significant improvements in glycaemic control with a low incidence of hypoglycemia, and weight gain. (S A Ross, 2015) Displays superiority over metformin monotherapy in terms of the improvement in glycemic control. A valuable new therapeutic option for improving glycemic control in patients with type 2 diabetes mellitus. (Gallwitz, 2013)